iView Therapeutics
PrivateLast Round
Series A
Extension
Jan 17, 2025
Total Funding Raised
$25.86M
Company Overview
iView Therapeutics is a clinical-stage biotechnology company that develops innovative topical drugs and gene therapies for ophthalmology, dermatology, and otolaryngology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iView Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
iView Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 17, 2025 | ||||
| Series A | Sep 20, 2021 | ||||
| Grant | Apr 11, 2019 | ||||
| Series A | Jun 27, 2018 | ||||
| Grant | Mar 26, 2018 | ||||
Grant | Sep 12, 2016 |
iView Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute of Allergy and Infectious Diseases | Grant |
| BioAdvance Capital | Series A |
| Cowin Capital | Series A |
| Proxima Ventures Ltd. | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 20, 2021
$25M raised from BioAdvance Capital and other investors.
- Mar 26, 2018
$280K grant from National Institute of Allergy and Infectious Diseases.
iView Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about iView Therapeutics's valuation, stock price, and market status.